Navigation Links
Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
Date:11/2/2012

PRINCETON, N.J., Nov. 2, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced an invitation to attend the presentation of data from its Phase 3 clinical studies.  The presentation will be held on November 5, 2012 at 7:30 a.m. pst in the Bernards Room at the Millennium Biltmore Hotel, 506 South Grand Avenue, Los Angeles. Participants are also invited to attend the presentation via a live webcast available through the "What's New" section at www.Omthera.com.  The webcast will be available for replay following the presentation.

The Phase 3 EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial was a 12 week, multi-center, randomized, double-blind, study of 399 patients, evaluating the efficacy and safety of three doses of Epanova in patients with fasting triglyceride levels of at least 500 mg/dL but less than 2000 mg/dL.  Patients were randomized into four dosing groups: Epanova 2g/day; Epanova 3g/day; Epanova 4g/day; and control (olive oil 4 g/day).  The primary endpoint of the trial was the percentage change in triglyceride level from baseline to week 12 and the secondary endpoint was the reduction in Non-HDL-C.

The Phase 3 ESPRIT (Epanova combined with a Statin in Patients with HypertRiglycerIdemia to Reduce Non-HDL CholesTerol) trial was a six-week, randomized, double-blind, parallel group study of 647 patients to assess the efficacy and safety of add-on Epanova to statin therapy in patients with persistent hypertriglyceridemia and high risk for cardiovascular disease. Patients were randomized into three dosing groups; Epanova 2g/day; Epanova 4g/day; and control (olive oil 4 g/day).  The primary objective of the study was to evaluate the efficacy of adding Epanova (2g or 4g daily) to statin monotherapy for lowering Non-HDL-C. Secondary objectives are to evaluate the safety of the Epanova and statin combination thera
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... July 30, 2014 DRE Medical — ... announce the launch of its Medical Trade Shows ... for medical professionals and equipment vendors. , The calendar ... conventions in the United States and around the world. ... and that number is always growing. , Information listed ...
(Date:7/30/2014)... Georgia (PRWEB) July 30, 2014 The ... and Technology Alliance of TAG (B&TA), today issued its ... TAG Excalibur Awards. , Interested companies have until August ... after which, Semi-Finalists will be selected by the Excalibur ... required to meet with the judges for interviewing process. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3
... Agency for Healthcare Research and Quality has reported that more ... treat burn victims is billed to Medicare or Medicaid, government ... ,According to statistics, the average charge is $59,600 ... the average charge for burn victims with private insurance ...
... is here to stay has made it necessary for health ... scenario Rush University Medical Center has pioneered the use of ... to respond quickly to infants in distress from any chemical ... of Public Health and the Health Resources and Services Administration ...
... race of a person was used as a basis to ... according to report published in the Journal of the American ... risky than that of their Indian and White compatriots, where ... policy is said to have been implemented by the South ...
... may be the reason for neural tube defects outbreak in ... ,The study published in the on line journal Environmental ... been infected by fungal toxins might give rise to neural ... pregnancy. ,Talking about “Neural tube defects” these ...
... error can make even a stone cry. Lis Noris, ... given radiation therapy, for brain tumor at Beatson Oncology ... to a rude shock of being the unfortunate recipient ... fatal. ,Doctors have admitted to human error, while ...
... a disease buster might be now challenged. ,A University of ... and grains had no reduced risk of two types of cancer ... ,The drawback of the study as perceived by some experts is ... of unhealthy food than the healthy foods., ,As said by ...
Cached Medicine News:Health News:Fungal toxins infected corn the reason for congenital defects 2Health News:Human Error: Teenager’s Renewed Zest for Life Nose-Dive 2Health News:Fat isn't all that bad: Reduction no predecessor of reduced disease 2
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
The Perfect Vac Quad Manifold allows one to four 96-well plates to be processed simultaneously. A single plate may be processed in 30 minutes; four plates are processed in 45 minutes....
... and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim with over ... ... ... ...
... The TurboVap Concentration Workstations from Caliper provide an automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down ... use around the world today. ... ... ...
Medicine Products: